51 partners, 11 European countries, 7 pharmaceutical companies.
These are the numbers of Harmony project and FISM is one of the partners involved for Italy.
Harmony, acronym for “Healthcare Alliance for Resourceful Drugs Offensive to Neoplasms in Hematology” is a project included within the European Program for Research and Innovation Horizon 2020.
Harmony’s goal is to study blood diseases by creating a large European database containing information (anonymous) on the pathology in order to be able to know them better and understand how to treat them more effectively.
Among the diseases of blood studied there are also myelodysplasia and FISM, with its register assets, can make an important contribution to research.
By involving all major players in the European landscape to combat these diseases, the project’s objective is to ensure that the outcomes can have immediate impact on the daily doctor-patient relationship and on the therapeutic approach to the disease.
This project started in January 2017 and will last for 5 years. It is funded by the IMI “Innovative Medicine Initiative”, the largest public / private European body that aims to accelerate the development of better and safer medicines for patients.